Collaboration Agreements (Ang2 Antibody) (Details) - Ang2 Antibody [Member] - USD ($) $ in Millions		3 Months Ended
Mar. 31, 2016	Mar. 31, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Deferred Revenue, Additions	$ 50.0
Percentage of global development cost to be paid by the collaboration partner under the collaboration	25.00%
Percentage of development cost for the territory outside the United States to be paid for under the collaboration	50.00%
Future development milestone payment the Company is eligible to receive		$ 80.0

Future development milestone payment the Company is eligible to receive.

No definition available.

Name:	regn_FuturedevelopmentmilestonepaymenttheCompanyiseligibletoreceive
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of development cost for the territory outside the United States previously required to be paid for under the collaboration.

+ References

No definition available.

+ Details

Name:	regn_PercentageofdevelopmentcostfortheterritoryoutsidetheUnitedStatespreviouslyrequiredtobepaidforunderthecollaboration
Namespace Prefix:	regn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of global development cost to be paid by the collaboration partner under the collaboration

+ References

No definition available.

+ Details

Name:	regn_Percentageofglobaldevelopmentcosttobepaidbythecollaborationpartnerunderthecollaboration
Namespace Prefix:	regn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=regn_Ang2AntibodyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: